An analog of glibenclamide selectively enhances autophagic degradation of misfolded [alpha]1-antitrypsin Z

• Published in: PloS one Vol. 14; no. 1; p. e0209748
• Main Authors: Wang, Yan, Cobanoglu, Murat C, Li, Jie, Hidvegi, Tunda, Hale, Pamela, Ewing, Michael, Chu, Andrew S, Gong, Zhenwei, Muzumdar, Radhika, Pak, Stephen C, Silverman, Gary A, Bahar, Ivet, Perlmutter, David H
• Format: Journal Article
• Language: English
• Published: Public Library of Science 23-01-2019
• Subjects: Drug therapy; Glyburide; Liver diseases; RNA interference; Trypsin
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0209748

The classical form of [alpha]1-antitrypsin deficiency (ATD) is characterized by intracellular accumulation of the misfolded variant [alpha]1-antitrypsin Z (ATZ) and severe liver disease in some of the affected individuals. In this study, we investigated the possibility of discovering novel therapeutic agents that would reduce ATZ accumulation by interrogating a C. elegans model of ATD with high-content genome-wide RNAi screening and computational systems pharmacology strategies. The RNAi screening was utilized to identify genes that modify the intracellular accumulation of ATZ and a novel computational pipeline was developed to make high confidence predictions on repurposable drugs. This approach identified glibenclamide (GLB), a sulfonylurea drug that has been used broadly in clinical medicine as an oral hypoglycemic agent. Here we show that GLB promotes autophagic degradation of misfolded ATZ in mammalian cell line models of ATD. Furthermore, an analog of GLB reduces hepatic ATZ accumulation and hepatic fibrosis in a mouse model in vivo without affecting blood glucose or insulin levels. These results provide support for a drug discovery strategy using simple organisms as human disease models combined with genetic and computational screening methods. They also show that GLB and/or at least one of its analogs can be immediately tested to arrest the progression of human ATD liver disease.